Results 1 to 10 of about 79,054 (352)
ERJ Open Research, 2021 Objectives Disease-specific, well-defined and validated clinical outcome measures are essential in designing research studies. Poorly defined outcome measures hamper pooling of data and comparisons between studies.
Florian Gahleitner +13 more
doaj +1 more source
Frontiers in Neurology, 2021 Background: Clinical trials for antiparkinsonian drugs aimed at managing motor complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into “troublesome” and “non-troublesome” categories.
Robert A. Hauser +4 more
doaj +1 more source
Proceedings of the 4th BEAT-PCD Conference and 5th PCD Training School
BMC Proceedings, 2020 Primary ciliary dyskinesia (PCD) is an inherited ciliopathy leading to chronic suppurative lung disease, chronic rhinosinusitis, middle ear disease, sub-fertility and situs abnormalities.
Laura E. Gardner +24 more
doaj +1 more source
Tardive Dyskinesia and Treatment Approaches [PDF]
Psikiyatride Güncel Yaklaşımlar, 2018 Tardive dyskinesia is an iatrogenic movement disorder with an incompletely determined etiology. Involuntary movements can effect oral, lingual, facial, corporal muscles and can be permanent. Tardive dyskinesia is one of the most important side effects of
Mehmet Emin Demirkol +3 more
doaj +1 more source
Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?
Clinical and Translational Neuroscience, 2021 Parkinson's disease (PD) is a chronic neurologic disease that has a great impact on the patient’s quality of life. The natural course of the disease is characterized by an insidious onset of symptoms, such as rest tremor, shuffling gait, bradykinesia ...
Oleg S. Levin +3 more
doaj +1 more source
Schizophrenia Bulletin, 1993 Neuroleptic-induced tardive dyskinesia (TD) continues to be a serious problem in the psychopharmacology of schizophrenia. The overall mean prevalence of TD among chronically neuroleptic-treated patients is approximately 24 percent. The annual incidence in younger adults is 4 to 5 percent. Aging is a major risk factor for TD.
D V, Jeste, M P, Caligiuri
openaire +2 more sources
Frontiers in Neurology, 2021 After long-term use of levodopa, Parkinson's patients almost inevitably develop dyskinesia, a kind of drug side effect manifesting as uncontrollable choreic movements and dystonia, which could be crippling yet have limited therapeutic options ...
Yi Wu +9 more
doaj +1 more source
Case Reports in Ophthalmology, 2022 General anesthesia is usually selected when patients cannot remain still during surgery with local anesthesia. However, damage to the lungs from positive pressure ventilation under general anesthesia is a major concern in patients with Parkinson’s ...
Takafumi Suzuki +5 more
doaj +1 more source
Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia
Frontiers in Aging Neuroscience, 2022 BackgroundThe pathophysiology of levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) is not well understood. Experimental data from numerous investigations support the idea that aberrant activity of D1 dopamine receptor-positive medium spiny ...
Shasha Gao +8 more
doaj +1 more source
Acta Psychiatrica Scandinavica, 1988 ABSTRACT— Tardive dyskinesia (TD) is a syndrome of involuntary movements that develops in predisposed individuals during neuroleptic drug treatment, with an average prevalence of 15%. Neuroleptic (antidopaminergic) drugs are the predominant etiological factor.
J, Gerlach, D E, Casey
openaire +6 more sources